Provectus formed an independent board, issuing a PR on this today. Jan Koe is added, while Eric drops off. My initial post on this topic is here.
Two takeaways from today's PR: First, the intent to apply for a listing on the NASDAQ when appropriate (more on this later).
Second, Eric's focus (under the shiny new title of CTO) on IP protection, among other things. With two key patents in process (i.e., RB synthesis meeting ICH guidelines, combination therapies), his work in this area remains critical to the value and valuation of Provectus.